Literature DB >> 21217185

High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy.

Kristin E Mondy1, John Gottdiener, E Turner Overton, Keith Henry, Tim Bush, Lois Conley, John Hammer, Charles C Carpenter, Erna Kojic, Pragna Patel, John T Brooks.   

Abstract

BACKGROUND: in the era of highly active antiretroviral therapy (HAART), human immunodeficiency virus (HIV)-infected persons have higher cardiovascular disease risk. Little is known about asymptomatic abnormalities in cardiac structure and function in this population.
METHODS: the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study) is a prospective, observational, multi-site cohort of 656 HIV-infected participants who underwent baseline echocardiography during 2004-2006. We examined prevalence of and factors associated with left ventricular systolic dysfunction (LVSD), diastolic dysfunction (DD), pulmonary hypertension (PHTN), left ventricular hypertrophy (LVH), and left atrial enlargement (LAE).
RESULTS: participant characteristics were as follows: median age, 41 years; 24% women; 29% non-Hispanic black; 73% receiving HAART; and median CD4+ cell count, 462 cells/μL. Among evaluable participants, 18% had LVSD, 26% had DD, 57% had PHTN (right ventricular pressure >30 mm Hg), 6.5% had LVH, and 40% had LAE. In multivariate analyses, significant factors (P < .05) associated with LVSD were history of MI, elevated highly sensitive C-reactive protein (hsCRP) level, and current tobacco smoking; for DD, elevated hsCRP level and hypertension; for PHTN, current use of ritonavir; for LVH, hypertension, diabetes, non-white race, female sex with elevated body mass index, calculated as the weight in kilograms divided by the square of height in meters, of ≥ 25, elevated hsCRP level, and current use of abacavir; for LAE, hypertension and recent marijuana use.
CONCLUSIONS: in this large contemporary HIV cohort, the prevalence of subclinical functional and structural cardiac abnormalities was greater than expected for age. Abnormalities were mostly associated with expected and often modifiable risks. Lifestyle modification should become a greater priority in the management of chronic HIV disease.

Entities:  

Mesh:

Year:  2010        PMID: 21217185     DOI: 10.1093/cid/ciq066

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  71 in total

1.  Injection drug use as a "second hit" in the pathogenesis of HIV-associated pulmonary hypertension.

Authors:  M Patricia George; Hunter C Champion; Mark T Gladwin; Karen A Norris; Alison Morris
Journal:  Am J Respir Crit Care Med       Date:  2012-06-01       Impact factor: 21.405

2.  Human Immunodeficiency Virus-Associated Myocardial Diastolic Dysfunction and Soluble ST2 Concentration in Tanzanian Adults: A Cross-Sectional Study.

Authors:  Justin R Kingery; Parag Goyal; Rahul Hosalli; Myung Hee Lee; Bernard Desderius; Fredrick Kalokola; Abel Makubi; Salama Fadhil; Saidi Kapiga; Dipan Karmali; Daniel Kaminstein; Richard Devereux; Margaret McNairy; Warren Johnson; Daniel Fitzgerald; Robert Peck
Journal:  J Infect Dis       Date:  2021-01-04       Impact factor: 5.226

3.  Resolution of dilated cardiomyopathy in an adolescent with change of a failing highly active antiretroviral drug therapy.

Authors:  Twalib Olega Aliku; Sulaiman Lubega; Peter Lwabi
Journal:  Afr Health Sci       Date:  2015-03       Impact factor: 0.927

4.  Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy.

Authors:  Daniele Pastori; Ivano Mezzaroma; Pasquale Pignatelli; Francesco Violi; Gregory Y H Lip
Journal:  Br J Clin Pharmacol       Date:  2019-01-11       Impact factor: 4.335

5.  Pulmonary hypertension in HIV-infected individuals.

Authors:  Priscilla Y Hsue; Ann F Bolger; Jeffrey N Martin
Journal:  Clin Infect Dis       Date:  2011-07-01       Impact factor: 9.079

Review 6.  Drug abuse and HIV-related pulmonary hypertension: double hit injury.

Authors:  Zachery J Harter; Stuti Agarwal; Pranjali Dalvi; Norbert F Voelkel; Navneet K Dhillon
Journal:  AIDS       Date:  2018-11-28       Impact factor: 4.177

Review 7.  Heart failure in patients with human immunodeficiency virus infection: epidemiology, pathophysiology, treatment, and future research.

Authors:  Joshua Remick; Vasiliki Georgiopoulou; Catherine Marti; Igho Ofotokun; Andreas Kalogeropoulos; William Lewis; Javed Butler
Journal:  Circulation       Date:  2014-04-29       Impact factor: 29.690

8.  Effect of left ventricular dysfunction and viral load on risk of sudden cardiac death in patients with human immunodeficiency virus.

Authors:  Brian S Moyers; Eric A Secemsky; Eric Vittinghoff; Joseph K Wong; Diane V Havlir; Priscilla Y Hsue; Zian H Tseng
Journal:  Am J Cardiol       Date:  2014-01-16       Impact factor: 2.778

Review 9.  What is the Current Knowledge About the Cardiovascular Risk for Users of Cannabis-Based Products? A Systematic Review.

Authors:  Emilie Jouanjus; Valentin Raymond; Maryse Lapeyre-Mestre; Valérie Wolff
Journal:  Curr Atheroscler Rep       Date:  2017-06       Impact factor: 5.113

10.  Bevacizumab in HIV-positive patients: concerns about safety and potential for therapeutic use.

Authors:  Nicolas Magné; Cyrus Chargari; Antonin Levy; Jean-Baptiste Guy; Yacine Merrouche; Jean-Philippe Spano
Journal:  J Chemother       Date:  2013-12-06       Impact factor: 1.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.